rs121908784
Variant summary
Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong
The NM_000492.4(CFTR):c.3744del(p.Lys1250ArgfsTer9) variant causes a frameshift change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00000496 in 1,613,480 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Pathogenic (★★★). Synonymous variant affecting the same amino acid position (i.e. S1248S) has been classified as Likely benign. Variant results in nonsense mediated mRNA decay.
Frequency
Consequence
NM_000492.4 frameshift
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 18 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
CFTR | NM_000492.4 | c.3744del | p.Lys1250ArgfsTer9 | frameshift_variant | 23/27 | ENST00000003084.11 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
CFTR | ENST00000003084.11 | c.3744del | p.Lys1250ArgfsTer9 | frameshift_variant | 23/27 | 1 | NM_000492.4 | P2 | |
ENST00000456270.1 | n.65+4887del | intron_variant, non_coding_transcript_variant | 3 |
Frequencies
GnomAD3 genomes AF: 0.0000131 AC: 2AN: 152126Hom.: 0 Cov.: 33
GnomAD3 exomes AF: 0.0000120 AC: 3AN: 250990Hom.: 0 AF XY: 0.00000737 AC XY: 1AN XY: 135636
GnomAD4 exome AF: 0.00000411 AC: 6AN: 1461354Hom.: 0 Cov.: 32 AF XY: 0.00000138 AC XY: 1AN XY: 726986
GnomAD4 genome AF: 0.0000131 AC: 2AN: 152126Hom.: 0 Cov.: 33 AF XY: 0.0000269 AC XY: 2AN XY: 74302
ClinVar
Submissions by phenotype
Cystic fibrosis Pathogenic:6
Pathogenic, criteria provided, single submitter | clinical testing | Myriad Genetics, Inc. | Nov 20, 2019 | NM_000492.3(CFTR):c.3744delA(K1250Rfs*9, aka 3876delA) is classified as pathogenic in the context of cystic fibrosis and is associated with the classic form of this disease. Sources cited for classification include the following: PMID 23974870. Classification of NM_000492.3(CFTR):c.3744delA(K1250Rfs*9, aka 3876delA) is based on the following criteria: The variant causes a premature termination codon that is expected to be targeted by nonsense-mediated mRNA decay and is reported in individuals with the relevant phenotype. Please note: this variant was assessed in the context of healthy population screening. - |
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Oct 27, 2023 | This sequence change creates a premature translational stop signal (p.Lys1250Argfs*9) in the CFTR gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in CFTR are known to be pathogenic (PMID: 1695717, 7691345, 9725922). This variant is present in population databases (rs121908784, gnomAD 0.009%). This premature translational stop signal has been observed in individual(s) with cystic fibrosis (PMID: 10777364, 11668613, 12865275, 15371903, 15858154, 22658665, 23974870, 26708955). This variant is also known as 3876delA. ClinVar contains an entry for this variant (Variation ID: 7231). For these reasons, this variant has been classified as Pathogenic. - |
Pathogenic, reviewed by expert panel | research | CFTR2 | Mar 17, 2017 | - - |
Pathogenic, no assertion criteria provided | literature only | OMIM | Mar 01, 2000 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Johns Hopkins Genomics, Johns Hopkins University | Jan 07, 2020 | Disease-causing CFTR variant (previously reported for this patient by mass spectrometry genotyping). See www.CFTR2.org for phenotype information. - |
Pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Jul 21, 2023 | The c.3744delA pathogenic mutation (also known as 3876delA), located in coding exon 23 of the CFTR gene, results from a deletion of one nucleotide at position 3744, causing a translational frameshift with a predicted alternate stop codon (p.K1250Rfs*9). This pathogenic mutation has been reported to be responsible for 1-5% of cystic fibrosis disease alleles in the Hispanic population (Wong LJ et al. Prenat Diagn. 2000;20(10):807-10; Schrijver I et al. J Mol Diagn. 2005;7(2):289-99; Sugarman EA et al. Genet Med. 2004;6(5):392-9). In one study, this mutation was detected in seven Hispanic individuals with cystic fibrosis, six of whom had a second CFTR mutation. These individuals presented with a severe clinical phenotype, including elevated sweat chloride levels, pancreatic insufficiency, and variable pulmonary function (Wang J et al. J Med Genet. 2000;37(3):215-8). This pathogenic mutation is associated with pancreatic insufficiency, decreased lung function, elevated sweat chloride levels, and a higher rate of Pseudomonas infection (Sosnay PR et al. Nat Genet. 2013;45(10):1160-1167). In addition to the clinical data presented in the literature, this alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation. - |
not provided Pathogenic:4
Pathogenic, criteria provided, single submitter | clinical testing | Mayo Clinic Laboratories, Mayo Clinic | Feb 09, 2022 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Quest Diagnostics Nichols Institute San Juan Capistrano | Oct 16, 2019 | The variant results in a shift of the reading frame, and is therefore predicted to result in the loss of a functional protein. Found in at least one patient with expected phenotype for this gene, and found in general population data at a frequency that is consistent with pathogenicity. - |
Pathogenic, criteria provided, single submitter | clinical testing | ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories | Sep 15, 2023 | The CFTR c.3744delA; p.Lys1250ArgfsTer9 variant (rs121908784), also known as 3876delA for traditional nomenclature, is reported in multiple individuals with pancreatic insufficient cystic fibrosis who carry an additional pathogenic variant in trans (CFTR2 database, Sosnay 2013, Wang 2000). This variant is reported as pathogenic in ClinVar (Variation ID: 7231). It is only observed on three alleles in the Genome Aggregation Database, indicating it is not a common polymorphism. This variant causes a frameshift by deleting a single nucleotide, so it is predicted to result in a truncated protein or mRNA subject to nonsense-mediated decay. Based on available information, this variant is considered to be pathogenic. References: CFTR2 database: https://cftr2.org/ Sosnay PR et al. Defining the disease liability of variants in the cystic fibrosis transmembrane conductance regulator gene. Nat Genet. 2013 Oct;45(10):1160-7. PMID: 23974870. Wang J et al. A novel mutation in the CFTR gene correlates with severe clinical phenotype in seven Hispanic patients. J Med Genet. 2000 Mar;37(3):215-8. PMID: 10777364. - |
Pathogenic, criteria provided, single submitter | clinical testing | Clinical Genetics Laboratory, Skane University Hospital Lund | May 27, 2022 | - - |
Cystic fibrosis;C0403814:Congenital bilateral aplasia of vas deferens from CFTR mutation Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Baylor Genetics | - | - - |
CFTR-related disorder Pathogenic:1
Pathogenic, no assertion criteria provided | clinical testing | Natera, Inc. | Mar 17, 2017 | - - |
Bronchiectasis with or without elevated sweat chloride 1 Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Baylor Genetics | Mar 22, 2024 | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at